Loading...
•
Sep 30, 2023
Inovio Q3 2023 Earnings Report
INOVIO reported financial results and operational highlights.
Key Takeaways
INOVIO reported third quarter results with significant progress on INO-3107, including Breakthrough Therapy designation and FDA feedback supporting a BLA submission under the accelerated approval program. The company is focused on commercialization strategy and aligning resources with late-stage clinical candidates.
Achieved significant progress with lead product candidate, INO-3107.
Received Breakthrough Therapy designation from FDA for INO-3107 as a potential treatment for RRP.
Received FDA feedback that Phase 1/2 trial data could be used to submit a BLA under Accelerated Approval program.
Accelerating commercialization strategy in preparation for an earlier launch of INO-3107.
Forward Guidance
INOVIO estimates its cash runway to extend into the second quarter of 2025, including a cash burn estimate of approximately $26 million for the fourth quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...